{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.","groups":[{"description":"Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression\n\nIntervention: Drug: melphalan 5mg/m\\^2 orally days 1-4 every 28 days until progression\n\nIntervention: Drug: prednisone 60mg/m\\^2, orally days 1-4 every 28 days until progression","id":"OG000","title":"Treatment (Lenalidomide, Melphalan, Prednisone)"}],"paramType":"NUMBER","populationDescription":"Patients who experienced an adverse event that is at least possibly related are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Every cycle during treatment up to 3 years","title":"Percentage of Participants With Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}